Document is current
Any future updates will be listed below
-
Authors
Li, Eric V. https://orcid.org/0000-0002-5506-5755
Kumar, Sai https://orcid.org/0000-0002-3577-3543
Aguiar, Jonathan A. https://orcid.org/0000-0001-5418-419X
Siddiqui, Mohammad R.
Sun, Zequn
Neill, Clayton https://orcid.org/0009-0003-3603-9580
Schaeffer, Edward M. https://orcid.org/0000-0003-0699-1899
Ross, Ashley E. https://orcid.org/0000-0001-7044-9688
Patel, Hiten D.
-
Funding
Funding for this research was provided by:
Prostate Cancer Foundation
Young Investigator Award
- License Information
-
More Information
Article History
Received: 22 May 2024
Revised: 24 November 2024
Accepted: 9 December 2024
First Online: 7 January 2025
Competing interests
: AER is engaged in consulting with American Society of Clinical Oncology (ASCO), Astellas, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Janssen Biotech, Lantheus Medical Imaging, Myovant Sciences, NCCN, Pfizer, Tempus Health, and Veracyte. EMS is engaged in consulting with Astellas, Lantheus Medical Imaging, Pfizer. The other contributing authors have no conflicts of interest to declare.
: The study was reviewed under IRB STU00214996 issued by Northwestern University. The study was performed in accordance with the Declaration of Helsinki.
